|
CRK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.5475000000007E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.25289999994583E-06 |
| Normal-vs-Stage2 |
1.499190E-03 |
| Normal-vs-Stage3 |
1.60535000000017E-05 |
| Normal-vs-Stage4 |
8.1207000002248E-07 |
| Stage1-vs-Stage2 |
8.317800E-01 |
| Stage1-vs-Stage3 |
1.601420E-01 |
| Stage1-vs-Stage4 |
1.788360E-02 |
| Stage2-vs-Stage3 |
2.135600E-01 |
| Stage2-vs-Stage4 |
4.500300E-02 |
| Stage3-vs-Stage4 |
3.393000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.39029999999918E-05 |
| Normal-vs-AfricanAmerican |
4.321500E-02 |
| Normal-vs-Asian |
6.23859999999699E-05 |
| Caucasian-vs-AfricanAmerican |
3.078000E-01 |
| Caucasian-vs-Asian |
4.902600E-01 |
| AfricanAmerican-vs-Asian |
2.090800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.91907999999019E-05 |
| Normal-vs-Female |
6.11729999999699E-05 |
| Male-vs-Female |
3.211800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.208300E-04 |
| Normal-vs-Age(41-60Yrs) |
1.69539000000052E-05 |
| Normal-vs-Age(61-80Yrs) |
4.85849999998234E-06 |
| Normal-vs-Age(81-100Yrs) |
1.715810E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.643700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.910200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.537800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.986800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.097600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.797200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.923800E-02 |
| Classical-VS-Follicular |
4.214800E-01 |
| Classical-VS-Other |
1.634970E-01 |
| Classical-VS-Normal |
2.581600E-04 |
| Tall-VS-Follicular |
1.935190E-01 |
| Tall-VS-Other |
5.648600E-01 |
| Tall-VS-Normal |
4.52299999997852E-06 |
| Follicular-VS-Other |
2.960000E-01 |
| Follicular-VS-Normal |
6.01219999999403E-05 |
| Other-VS-Normal |
1.231670E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.55130000000425E-05 |
| Normal-vs-N1 |
6.11600000000045E-05 |
| N0-vs-N1 |
3.549400E-01 |
|
|
